US Broker Ratings

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating a Potential 18.96% Upside in Healthcare Diagnostics

Fulgent Genetics, Inc. (NASDAQ: FLGT) operates in the dynamic Healthcare sector, specifically within the Diagnostics & Research industry. Headquartered in El Monte, California, this U.S.-based company has carved a niche..

Mind Medicine (MNMD) Stock Analysis: Exploring a 106% Potential Upside in the Biotech Space

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a promising player in the biotechnology sector, is making waves with its innovative approach to treating brain health disorders. Headquartered in New York, the..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A 160% Potential Upside Sparks Investor Interest

Zevra Therapeutics, Inc. (ZVRA), a promising player in the biotechnology industry, has been capturing the attention of investors with its remarkable potential upside. The company, headquartered in Celebration, Florida, and..

Bicycle Therapeutics plc (BCYC) Stock Report: A 191.57% Potential Upside in the Biotech Arena

Bicycle Therapeutics plc (NASDAQ: BCYC), a burgeoning entity in the biotechnology sector, is drawing significant attention from investors with its impressive potential upside of 191.57%. This clinical-stage pharmaceutical company, headquartered..

Owens & Minor, Inc. (OMI) Stock Analysis: A Look at Its 123.53% Potential Upside

Owens & Minor, Inc. (NYSE: OMI), a key player in the healthcare sector, offers intriguing prospects for investors despite current challenges. Trading at a modest $2.55 per share, OMI has..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a 147.99% Potential Upside for Investors

LifeMD, Inc. (NASDAQ: LFMD), a prominent player in the healthcare sector, offers an intriguing proposition for investors seeking opportunities in the burgeoning telehealth industry. With a market capitalization of $179.55..

REGENXBIO Inc. (RGNX) Stock Analysis: Eyeing a 127.62% Upside with Robust Buy Ratings

Investors looking at the biotechnology sector should keep a close eye on REGENXBIO Inc. (RGNX), a clinical-stage biotech firm specializing in gene therapies. With its headquarters in Rockville, Maryland, REGENXBIO..

Rocket Pharmaceuticals, Inc. (RCKT) Investor Outlook: Exploring a 132.59% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a prominent player in the biotechnology sector, has been the subject of considerable attention from investors, primarily due to its promising pipeline of gene therapies..

Iovance Biotherapeutics (IOVA) Stock Analysis: Unveiling a 275% Potential Upside in the Biotech Sector

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a key player in the biotechnology sector, has attracted considerable attention from investors with its promising portfolio of therapies aimed at combatting metastatic melanoma and..

Zenas BioPharma (ZBIO) Stock Analysis: Exploring an 18% Upside Potential with Strong Buy Ratings

Zenas BioPharma, Inc. (NASDAQ: ZBIO), a clinical-stage biopharmaceutical company, has been capturing the attention of investors with its promising pipeline and significant upside potential. As a player in the burgeoning..

Delcath Systems, Inc. (DCTH) Stock Analysis: Poised for a 122% Upside in the Medical Device Sector

Delcath Systems, Inc. (NASDAQ: DCTH) is capturing investor attention with a remarkable potential upside of 122.60%, driven by its innovative approach to treating liver cancers. This New York-based healthcare company..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Navigating a 32.87% Potential Upside in Pediatric Orthopedics

OrthoPediatrics Corp. (NASDAQ: KIDS), a trailblazer in the pediatric medical device industry, presents a compelling opportunity for investors seeking growth in the healthcare sector. With a market capitalization of $455.66..

CareDx, Inc. (CDNA) Investor Outlook: Analyzing a 15% Potential Upside in the Healthcare Diagnostics Sector

CareDx, Inc. (NASDAQ: CDNA), a prominent player in the healthcare diagnostics sector, has captured the interest of investors with a noteworthy potential upside of 15.06%, according to recent analyst ratings...

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 75% Potential Upside for Biotech Innovators

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, is catching the eye of investors with a notable 75.42% potential upside, driven by its promising pipeline and strategic partnerships. Headquartered..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Exploring a 78.47% Potential Upside for Savvy Investors

Eton Pharmaceuticals, Inc. (ETON), a burgeoning player in the healthcare sector, is garnering attention from investors with its impressive growth trajectory and promising financial outlook. Based in Deer Park, Illinois,..

Beta Bionics, Inc. (BBNX) Investor Outlook: A Healthcare Pioneer with Strong Revenue Growth and Analyst Confidence

Beta Bionics, Inc. (NASDAQ: BBNX) is making waves in the healthcare sector, specifically within the medical devices industry. Focused on improving the lives of individuals requiring insulin, this U.S.-based company..

Weave Communications, Inc. (WEAV) Stock Analysis: Exploring a 63.78% Potential Upside

Weave Communications, Inc. (NYSE: WEAV) is a burgeoning player in the Health Information Services industry, providing cutting-edge customer experience and payment software solutions to small and medium-sized healthcare businesses. With..

Upstream Bio, Inc. (UPB) Stock Analysis: A Biotech Gem with a 69% Upside Potential

Upstream Bio, Inc. (UPB), a promising player in the biotechnology sector, has captured investor interest with its focus on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Headquartered in..

AxoGen, Inc. (AXGN) Stock Analysis: Evaluating the Growth Potential Amidst a Robust 23.5% Revenue Surge

AxoGen, Inc. (NASDAQ: AXGN), a key player in the healthcare sector’s medical devices industry, has been making waves with its innovative solutions for peripheral nerve regeneration and repair. Headquartered in..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a 54% Potential Upside in Biotech Innovation

Xencor, Inc. (NASDAQ: XNCR), an intriguing player in the biotechnology industry, offers a compelling narrative for investors focused on growth and innovation within the healthcare sector. With a market capitalization..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds